Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR
IPSEN SA S/ADR (IPSEY)
NASDAQ:AMEX Investor Relations:
ipsen.com/investors
Company Research
Source: GlobeNewswire
IPN01203 data to be presented at coveted New Drugs on the Horizon program session, demonstrating early potential of this novel T cell activator to transform care in solid tumors ITGA2 revealed as novel target of Ipsen’s investigational antibody drug conjugate IPN60300, over-expressed across numerous solid tumor typesPreclinical data show potential of Ipsen’s growing collection of investigational medicines, leveraging precision immuno-modulation to deliver differentiated anti-tumor activity PARIS, FRANCE, 18 March 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the presentation of new preclinical data across multiple early development programs currently in Phase I clinical trials, at the American Association of Cancer Research (AACR) congress. These latest data include an oral presentation for T cell activator (TCA) IPN01203 to be presented during the coveted New Drugs on the Horizon program session, highlighting the differentiated mode of action, activating Vß6/Vß10 T cells.
Show less
Read more
Impact Snapshot
Event Time:
IPSEY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IPSEY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IPSEY alerts
High impacting IPSEN SA S/ADR news events
Weekly update
A roundup of the hottest topics
IPSEY
News
- Ipsen appoints Michelle C. Werner as EVP, President of North AmericaGlobeNewswire
- IPSEN (OTCMKTS:IPSEY) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.MarketBeat
- Ipsen SA (IPSEY) Full Year 2025 Earnings Call Highlights: Strong Sales Growth and Strategic ... [Yahoo! Finance]Yahoo! Finance
- Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidanceGlobeNewswire
- Origami Therapeutics Announces Global Collaboration with Ipsen to Advance Protein Degrader ProgramBusiness Wire